CRSP - CRISPRセラピュ―ティクス （CRISPR Therapeutics AG） CRISPRセラピュ―ティクスCRSPのチャート
CRSPの企業情報
| symbol | CRSP |
|---|---|
| 会社名 | CRISPR Therapeutics AG （CRISPRセラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA) which is comprised of a crRNA component and a tracrRNA component either individually or combined together as a single guide RNA. The Company has business operations in London the United Kingdom as well as research and development operations in Cambridge the United States. CRISPRセラピュ―ティクスはスイスのバイオ医薬品企業。ゲノム編集に従事し、遺伝子ベ―スの病気の治療に使用される「CRISPR/Cas9」プラットフォ―ムを開発する。スイス、米国、英国で事業を展開する。「CRISPR」ベ―スの開発をバイエルとバ―テックス・ファ―マシュ―ティカルズと協業する。本社はバ―ゼル。 |
| 本社所在地 | Baarerstrasse 14 Zug 6300 CHE |
| 代表者氏名 | Rodger Novak ロジャーノヴァク |
| 代表者役職名 | Chairman of the Board of Directors President Founder |
| 電話番号 | +41 41-561-3277 |
| 設立年月日 | 41548 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 127人 |
| url | www.crisprtx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/crsp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -83.54900 |
| 終値（lastsale） | 36.6 |
| 時価総額（marketcap） | 1732197333.6 |
| 時価総額 | 時価総額（百万ドル） 1894.215 |
| 売上高 | 売上高（百万ドル） 37.15800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1574.478 |
| 当期純利益 | 当期純利益（百万ドル） -84.94600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Crispr Therapeutics AG revenues decreased 61% to $2.4M. Net loss increased 52% to $66.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 31% to $37.1M (expense) Stock-based Compensation in R&D increase from $3.7M to $8.1M (expense). |
CRSPのテクニカル分析
CRSPのニュース
CRISPR Therapeutics (NASDAQ:CRSP) Releases Quarterly Earnings Results 2021/02/17 21:12:42 Transcript Daily
CRISPR Therapeutics (NASDAQ:CRSP) posted its quarterly earnings results on Monday. The company reported ($1.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.27) by ($0.23), MarketWatch Earnings reports. CRISPR Therapeutics had a negative return on equity of 20.72% and a negative net margin of 273.10%. Shares of NASDAQ:CRSP traded down $5.65 on […]
Chardan Capital Stick to Their Buy Rating for Crispr Therapeutics AG By Investing.com 2021/02/17 13:20:00 Investing.com
Chardan Capital Stick to Their Buy Rating for Crispr Therapeutics AG
Thematic ETFs boom, drawing punters and concern 2021/02/12 16:33:59 Economic Times India
LONDON: From cat food to cannabis, it's boom time for quirky ETFs offering the chance to punt on niche themes in fast-growth sectors, but their huge gains are unnerving some who see them as another price-inflated asset that may threaten market stability.While Reddit "gamestonks" have grabbed recent headlines, retail investors are also credited with large flows into exchange-traded funds - basically a tradable basket of shares - swelling their assets by more than $1 trillion last year, according to Refinitiv.And growth has been especially notable in ETFs that aim to harness returns from themes that capitalise on societal and economic trends, from space travel to pet care, and marijuana to medical tech.Such ETFs, which are bought and sold like shares, more than doubled their assets under management last year to $140 billion, Citi analyst Scott Chronert says, describing inflows as having gone "nearly parabolic".Thematic ETFs in EMEA alone have received $4 billion so far this year, according to the bank, a figure Chronert said would grow "as investors continue to demand more precise positioning".
Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day 2021/02/11 14:01:02 Yahoo Finance UK
Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day
CRISPR Therapeutics Is it time to Buy before this week’s earning report Stock market Insights & financial analysis 2021/02/10 13:18:00 Stock Market Daily
CRISPR Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other Stocks 2020/10/07 14:04:00 Barron's
This year’s Nobel Prize for chemistry was awarded Wednesday to the two discoverers of Crispr/Cas9, which has led to gene-editing treatments for inherited illnesses like sickle-cell anemia.
Crispr Therapeutics Gets an Upgrade but Needs Help on the Charts 2020/10/05 18:23:32 The Street RealMoney
Crispr Therapeutics Gets an Upgrade but Needs Help on the Charts…CRSP
Top Analyst Upgrades and Downgrades: Amex, AT&T, CRISPR, DocuSign, ONEOK, Regeneron, Shopify, Tesla and More – 24/7 Wall St. 2020/10/05 13:09:07 24/7 Wall street
Monday's top analyst upgrades and downgrades included American Express, AT&T, CRISPR Therapeutics, DocuSign, ONEOK, Regeneron Pharmaceuticals, Shopify and Tesla.
CRISPR Therapeutics Stock Is a Strong Buy on the Dip 2020/09/09 15:36:01 InvestorPlace
CRSP stock has pulled back 13% in the last two sessions on no news. The dip allows investors into a strong long-term story at a lower price.
CRISPR Therapeutics Stock Shows It Has Good Genes 2020/08/18 15:41:07 The Street RealMoney
CRISPR Therapeutics Stock Shows It Has Good Genes in Its Charts…CRSP
CRISPR Therapeutics Stock Is a Strong Buy on the Dip 2020/09/09 15:36:01 InvestorPlace
CRSP stock has pulled back 13% in the last two sessions on no news. The dip allows investors into a strong long-term story at a lower price.
CRISPR Therapeutics Stock Shows It Has Good Genes 2020/08/18 15:41:07 The Street RealMoney
CRISPR Therapeutics Stock Shows It Has Good Genes in Its Charts…CRSP
CRISPR Therapeutics: My #1 High-Risk Investment Idea (NASDAQ:CRSP) 2020/08/14 18:55:02 Seeking Alpha
CRISPR Therapeutics sits at the forefront of the CRISPR/CAS9 gene-editing breakthrough. CTX001 data for Sickle Cell Disease & Beta-Thalassemia is extremely promising.